Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure.

31 Of note, the phase II MonarcHER trial showed that, in HR-positive/HER2-positive ABC patients, the combination of abemaciclib–fulvestrant–trastuzumab improves mPFS (8.3 months, 95% CI: 5.9-12.6 months) over trastuzumab chemotherapy (5.7 months, 95% CI: 5.4-7.0 months) with hazard ratio of 0.67 (95% CI: 0.45-1.00, P = 0.051), with an interesting trend for improved mOS among patients with luminal versus non-luminal subtypes (31.7 versus 19.7 months, hazard ratio 0.68, 95% CI: 0.46-1.00). 75 Altogether, these trials evidenced the importance of implementing tailored therapeutic options for different patients’ populations.

also in 454 other papers